Session Information

WCLC 2017

18th World Conference on Lung Cancer

Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan

Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.
Presentation Date(s):
- Oct 15 - 18, 2017
- Total Presentations: 2295
Register to Attend WCLC Return to WCLC 2017 Website Switch to Virtual Meeting
Enter Virtual Meeting Access Code

All Days Saturday
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18

Filter Results:

Show Only CME Accredited Sessions

18982

+
JCSE 01 - Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West
- 07:30 - 11:30
- 10/15/2017
- Location: F203 (Annex Hall)
- Type: Joint Session IASLC/CSCO/CAALC
- Track: Immunology and Immunotherapy
- Moderators:C. Bai, Fred R. Hirsch, Tony SK Mok, Yi-Long Wu
- 22310
  
  +
  
  JCSE 01.18 - Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients
  
  11:30 - 11:30 | Presenter: Yun Fan | Author(s): K. Chen, X. Yu, H. Wang, Z. Huang, Y. Xu, L. Gong
  Abstract
  
  Loading...
20203

+
P1.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- 22483
  
  +
  
  P1.01-077 - Oncogenic Potential of a Novel HER2 755PL In-Frame (HER2PL) Mutation in Lung Adenocarcinoma
  
  09:30 - 09:30 | Presenter: Anya Maan-Yuh Lin | Author(s): C. Yang, J. Lin, James Chih-Hsin Yang, H. Wang
  Abstract
  
  Loading...
18973

+
P2.01 - Advanced NSCLC
- 09:00 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- 23152
  
  +
  
  P2.01-029 - Real World Report of Clinical Outcomes of Bevacizumab in First-Line or Later-Line Treatment for Patients with Advanced NSCLC
  
  09:00 - 09:00 | Presenter: Yalei Wang | Author(s): X. Hao, Yixiang Zhu, X. Hu, H. Wang, Y. Liu, Yuxin Mu, Junling Li, Y. Wen, Y. Wang
  Abstract
  
  Loading...
- 23153
  
  +
  
  P2.01-030 - Real World Study of Bevacizumab-Contained Regimen as First Line Therapy in Chinese Patients with Advanced NSCLC
  
  09:00 - 09:00 | Presenter: Yuxin Mu | Author(s): P. Xing, Y. Wang, X. Hao, X. Hu, H. Wang, Y. Liu, Y. Wen, Yalei Wang, J. Li
  Abstract
  
  Loading...
20167

+
P2.03 - Chemotherapy/Targeted Therapy
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- 23284
  
  +
  
  P2.03-013 - Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients
  
  09:30 - 09:30 | Presenter: Yun Fan | Author(s): K. Chen, X. Yu, H. Wang, Z. Huang, Y. Xu, L. Gong
  Abstract
  
  Loading...
20136

+
MA 14 - Diagnostic Radiology, Staging and Screening for Lung Cancer I
- 15:45 - 17:30
- 10/17/2017
- Location: F205 + F206 (Annex Hall)
- Type: Mini Oral
- Track: Radiology/Staging/Screening
- Moderators:H. Kondo, Hong Kwan Kim
- 23731
  
  +
  
  MA 14.07 - Randomized Lung Cancer Screening with Low-Dose CT in China: A Specific Risk-Based Screening for Chinese Population
  
  16:25 - 16:30 | Presenter: Baohui Han | Author(s): H. Wang, J. Teng, J. Ye, Q. Chen, Y. Zhang, W. Yang, F. Qian
  Abstract
  
  Loading...
20139

+
MA 16 - Mediastinal, Tracheal and Esophageal Tumor: Multimodality Approaches
- 15:45 - 17:30
- 10/17/2017
- Location: Room 313 + 314
- Type: Mini Oral
- Track: Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
- Moderators:K. Shibuya, Francoise Mornex
- 23760
  
  +
  
  MA 16.06 - Minimally Invasive Thoracoscopic Thymectomy for Early-Stage Thymomas: Modified Subxiphoid Approach Versus Unilateral Approach
  
  16:20 - 16:25 | Presenter: Jian-Yong Ding | Author(s): H. Wang
  Abstract
  
  Loading...
18975

+
P3.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- 23928
  
  +
  
  P3.01-069 - Three Treatments for EGFR-Mutant Non-Small-Cell Lung Cancer with Brain Metastases
  
  09:30 - 09:30 | Presenter: Yun Fan | Author(s): X. Yu, H. Wang
  Abstract
  
  Loading...
- 23946
  
  +
  
  P3.01-087 - Impact Factor Analysis for Efficacy and Prognosis of Anlotinib in NSCLC as Third-Line Treatment: Data from Trial ALTER 0303
  
  09:30 - 09:30 | Presenter: Kai Li | Author(s): J. Wang, Baohui Han, Y.Z. Zhao, Qiming Wang, L. Zhang, J. Shi, Z. Wang, J. He, Yuankai Shi, Ying Cheng, W. Chen, X. Wang, Y. Luo, K. Nan, F. Jin, J. Dong, B. Li, Y. Chen, J. Zhou, D. Wang, X. Zhou, Y. Yu, L. Chen, A. Liu, J. Huang, C. Huang, B. Cao, J. Chen, R. Ma, Z. Yu, C. Ding, H. Wang
  Abstract
  
  Loading...
18974

+
P3.02 - Biology/Pathology
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- 24014
  
  +
  
  P3.02-066 - Wild-Type KRAS Mediates Growth Inhibition and Resistance to MEK Inhibitors through Dimerization with Mutant KRAS in Lung Adenocarcinoma
  
  09:30 - 09:30 | Presenter: Chiara Ambrogio | Author(s): J. Kohler, Z. Zhou, H. Wang, R. Paranal, M. Capelletti, C. Caffarra, S. Li, Q. Lv, S. Gondi, J.C. Hunter, R. Chiarle, D. Santamaría, K.D. Westover, Pasi A Jänne
  Abstract
  
  Loading...

Session Information

WCLC 2017

18th World Conference on Lung Cancer

Enter Virtual Meeting Access Code

+

JCSE 01 - Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West

+

JCSE 01.18 - Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

+

P1.01 - Advanced NSCLC

+

P1.01-077 - Oncogenic Potential of a Novel HER2 755PL In-Frame (HER2PL) Mutation in Lung Adenocarcinoma

+

P2.01 - Advanced NSCLC

+

P2.01-029 - Real World Report of Clinical Outcomes of Bevacizumab in First-Line or Later-Line Treatment for Patients with Advanced NSCLC

+

P2.01-030 - Real World Study of Bevacizumab-Contained Regimen as First Line Therapy in Chinese Patients with Advanced NSCLC

+

P2.03 - Chemotherapy/Targeted Therapy

+

P2.03-013 - Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

+

MA 14 - Diagnostic Radiology, Staging and Screening for Lung Cancer I

+

MA 14.07 - Randomized Lung Cancer Screening with Low-Dose CT in China: A Specific Risk-Based Screening for Chinese Population

+

MA 16 - Mediastinal, Tracheal and Esophageal Tumor: Multimodality Approaches

+

MA 16.06 - Minimally Invasive Thoracoscopic Thymectomy for Early-Stage Thymomas: Modified Subxiphoid Approach Versus Unilateral Approach

+

P3.01 - Advanced NSCLC

+

P3.01-069 - Three Treatments for EGFR-Mutant Non-Small-Cell Lung Cancer with Brain Metastases

+

P3.01-087 - Impact Factor Analysis for Efficacy and Prognosis of Anlotinib in NSCLC as Third-Line Treatment: Data from Trial ALTER 0303

+

P3.02 - Biology/Pathology

+

P3.02-066 - Wild-Type KRAS Mediates Growth Inhibition and Resistance to MEK Inhibitors through Dimerization with Mutant KRAS in Lung Adenocarcinoma

Stay Connected